enprofylline has been researched along with Asthma in 39 studies
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients were recruited from 18 centers and 4 countries to participate in a 1-month double-blind comparison of enprofylline or theophylline in the treatment of asthma and were subsequently maintained on a regimen with the assigned medication for a further 11 months." | 9.07 | Long-term xanthine therapy of asthma. Enprofylline and theophylline compared. International Enprofylline Study Group. ( Chapman, KR; Kallen, A; Ljungholm, K, 1994) |
| "The efficacy and safety of different regimens of intravenously administered enprofylline, an anti-asthma xanthine, were evaluated in a randomized open study, including 155 patients with acute exacerbation of obstructive lung disease." | 9.07 | Efficacy of enprofylline in acute airway obstruction. ( Andersen, JR; Boethius, G; Eriksson, G; Hagman, A; Helsted, M; Lund, B; Månsson, T; Matsols, H; Rosenhall, L; Sandström, T, 1991) |
| "We assessed the efficacy and side effects of oral enprofylline in the maintenance therapy of 206 asthmatics 19 to 71 yr of age." | 9.06 | A placebo-controlled dose-response study of enprofylline in the maintenance therapy of asthma. ( Bryant, D; Chapman, KR; Inouye, T; Koskinen, S; Marlin, GE; Mitchell, C; Osen, SS; Pedersen, B; Ringdal, N; Ruffin, R, 1989) |
| "Five different doses of enprofylline, a 3-propylxanthine, were compared with a standard dose of theophylline in 135 episodes of acute asthma in a double-blind study." | 9.06 | Efficacy of enprofylline, a new bronchodilating xanthine, in acute asthma. ( Boe, J; Eriksson, G; Ljungholm, K, 1987) |
| "Fifteen asthmatic outpatients were randomly treated during two periods of 14 days each with sustained-release preparations of either enprofylline (3-propyl-xanthine) or theophylline (Theo-Dur) in a double-blind crossover study." | 9.06 | Enprofylline and theophylline slow-eroding tablets in the treatment of asthma: a comparison. ( Eriksson, G; Laursen, LC; Weeke, B, 1986) |
| "Thirty-nine patients with asthma requiring acute treatment were included in a randomized, double-blind, parallel study which compared the effect of enprofylline (1." | 9.06 | Comparison of enprofylline and theophylline for intravenous treatment of acute asthma. ( Eriksson, G; Haahtela, T; Venho, K, 1986) |
| "Enprofylline, a drug without adenosine antagonism and theophylline, a potent adenosine antagonist, were compared, double-blind, randomized, in acute asthma (n = 33)." | 9.06 | Comparison between theophylline and an adenosine non-blocking xanthine in acute asthma. ( Amundsen, T; Brenna, E; Eriksson, G; Holte, S; Källén, AG; Naustdal, T; Persson, CG; Storstein, L; Syvertsen, U; Vilsvik, JS, 1990) |
| "We compared the bronchodilating effects of intravenously administered enprofylline (2 mg/kg) with nebulized terbutaline (10 mg) in patients presenting to hospital with acute asthma in a multicenter double-blind parallel study." | 9.06 | Comparison of the effects of nebulized terbutaline with intravenous enprofylline in patients with acute asthma. ( Bryant, D; Burdon, J; Marlin, G; Mitchell, C; O'Hehir, R; Ruffin, R; Webb, S; Wilson, J; Woolcock, A, 1988) |
| "A double-blind crossover study has been performed in 14 patients with moderately severe chronic asthma to compare the bronchodilator efficacy of two dosage regimens of intravenous enprofylline (high dose = 2 mg/kg bolus and 1 mg/kg/hour infusion; low dose = 1 mg/kg bolus and 500 micrograms/kg/hour infusion) with aminophylline (5 mg/kg/bolus and 500 micrograms/kg/hour infusion) and placebo." | 9.06 | Enprofylline in chronic asthma. ( Capewell, S; Chapman, BJ; Crompton, GK; Frame, MH; McDonald, C, 1988) |
| "Twenty-five asthmatic outpatients were treated for 3 one-week periods with either enprofylline slowly eroding 300 mg tablets t." | 9.05 | Continuous treatment of asthmatic patients with enprofylline and theophylline. ( Johannesson, N; Laursen, LC; Weeke, B, 1984) |
| "The bronchodilating effect of two doses of peroral enprofylline was compared with placebo in 24 asthmatic patients." | 9.05 | Enprofylline--effects of a new bronchodilating xanthine derivative in asthmatic patients. ( Dirksen, A; Djurup, R; Johannesson, N; Laursen, LC; Munch, EP; Taudorf, E; Weeke, B, 1983) |
| "Eight asthmatic out-patients with a history of exercise-induced asthma (EIA) were randomly treated with intravenously administered enprofylline 1." | 9.05 | Effects of enprofylline and theophylline on exercise-induced asthma. ( Johannesson, N; Laursen, LC; Weeke, B, 1985) |
| "In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined." | 9.05 | Intravenous administration of enprofylline to asthmatic patients. ( Fagerström, PO; Johannesson, N; Laursen, LC; Weeke, B, 1983) |
| "The bronchodilator effect and side-effects of a single oral dose of enprofylline were compared with the corresponding actions of a therapeutic dose of theophylline in 20 asthmatic patients, in a randomized cross-over clinical trial." | 9.05 | Comparison of oral enprofylline and theophylline in asthmatic patients. ( Johannesson, N; Laursen, LC; Søndergaard, I; Weeke, B, 1984) |
| " In separate studies we found that enprofylline, an antiasthmatic previously thought to lack adenosine antagonistic properties, is as effective as theophylline as an antagonist of A2b receptors at concentrations achieved clinically." | 7.69 | Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. ( Biaggioni, I; Feoktistov, I, 1995) |
| "Several lines of evidence support the hypothesis that adenosine contributes to asthma." | 7.69 | Role of adenosine in asthma. ( Biaggioni, I; Feoktistov, I, 1996) |
| "Nine patients (3 women), aged 29-78 years, with acute asthma were treated with the antiasthma xanthine, enprofylline, in an open-design study without a reference drug." | 7.67 | Intravenous infusion of enprofylline with an exponentially decreasing drug concentration in acute asthma. ( Arnman, K; Borgström, L; Conradson, TB; Willén, B, 1989) |
| "The pharmacokinetics of enprofylline (3-propylxanthine) were studied in 10 children with asthma (mean age 7." | 7.67 | Pharmacokinetics of enprofylline administered intravenously and as a sustained-release tablet at steady state in children with asthma. ( Simons, FE; Simons, KJ; Watson, WT, 1988) |
| "The pharmacokinetics of intravenous enprofylline has been studied in 8 children with asthma." | 7.67 | Enprofylline pharmacokinetics in children with asthma. ( Borgå, O; Hultqvist, C, 1987) |
| "Enprofylline is a novel xanthine derivative with negligible adenosine antagonizing ability." | 6.66 | Additive bronchodilator effects of terbutaline and enprofylline in asthma. ( Lunell, E; Rasmussen, JB, 1987) |
| "Enprofylline was given i." | 5.27 | Intravenous enprofylline in asthma patients. ( Andersson, KE; Lunell, E; Persson, CG; Svedmyr, N, 1984) |
| "Pretreatment with lidocaine, the beta-receptor agonist, terbutaline, or the adenosine non-blocking xanthine, enprofylline, inhibited the capsaicine induced inflammatory response." | 5.27 | Anti-asthma drugs and capsaicine-induced microvascular effects in lower airways. ( Erjefält, I; Persson, CG, 1985) |
| "Patients were recruited from 18 centers and 4 countries to participate in a 1-month double-blind comparison of enprofylline or theophylline in the treatment of asthma and were subsequently maintained on a regimen with the assigned medication for a further 11 months." | 5.07 | Long-term xanthine therapy of asthma. Enprofylline and theophylline compared. International Enprofylline Study Group. ( Chapman, KR; Kallen, A; Ljungholm, K, 1994) |
| "The efficacy and safety of different regimens of intravenously administered enprofylline, an anti-asthma xanthine, were evaluated in a randomized open study, including 155 patients with acute exacerbation of obstructive lung disease." | 5.07 | Efficacy of enprofylline in acute airway obstruction. ( Andersen, JR; Boethius, G; Eriksson, G; Hagman, A; Helsted, M; Lund, B; Månsson, T; Matsols, H; Rosenhall, L; Sandström, T, 1991) |
| "A double-blind crossover study has been performed in 14 patients with moderately severe chronic asthma to compare the bronchodilator efficacy of two dosage regimens of intravenous enprofylline (high dose = 2 mg/kg bolus and 1 mg/kg/hour infusion; low dose = 1 mg/kg bolus and 500 micrograms/kg/hour infusion) with aminophylline (5 mg/kg/bolus and 500 micrograms/kg/hour infusion) and placebo." | 5.06 | Enprofylline in chronic asthma. ( Capewell, S; Chapman, BJ; Crompton, GK; Frame, MH; McDonald, C, 1988) |
| "We assessed the efficacy and side effects of oral enprofylline in the maintenance therapy of 206 asthmatics 19 to 71 yr of age." | 5.06 | A placebo-controlled dose-response study of enprofylline in the maintenance therapy of asthma. ( Bryant, D; Chapman, KR; Inouye, T; Koskinen, S; Marlin, GE; Mitchell, C; Osen, SS; Pedersen, B; Ringdal, N; Ruffin, R, 1989) |
| "We compared the bronchodilating effects of intravenously administered enprofylline (2 mg/kg) with nebulized terbutaline (10 mg) in patients presenting to hospital with acute asthma in a multicenter double-blind parallel study." | 5.06 | Comparison of the effects of nebulized terbutaline with intravenous enprofylline in patients with acute asthma. ( Bryant, D; Burdon, J; Marlin, G; Mitchell, C; O'Hehir, R; Ruffin, R; Webb, S; Wilson, J; Woolcock, A, 1988) |
| "Twenty-four patients (five women) aged 53-72 yr with both ischemic heart disease and asthma or chronic bronchitis receiving oral beta 2-agonists also received additional bronchodilating therapy with theophylline (600 mg daily), enprofylline (600 mg daily) or placebo." | 5.06 | Arrhythmogenicity from combined bronchodilator therapy in patients with obstructive lung disease and concomitant ischemic heart disease. ( Conradson, TB; Eklundh, G; Olofsson, B; Pahlm, O; Persson, G, 1987) |
| "Thirty-nine patients with asthma requiring acute treatment were included in a randomized, double-blind, parallel study which compared the effect of enprofylline (1." | 5.06 | Comparison of enprofylline and theophylline for intravenous treatment of acute asthma. ( Eriksson, G; Haahtela, T; Venho, K, 1986) |
| "Enprofylline, a drug without adenosine antagonism and theophylline, a potent adenosine antagonist, were compared, double-blind, randomized, in acute asthma (n = 33)." | 5.06 | Comparison between theophylline and an adenosine non-blocking xanthine in acute asthma. ( Amundsen, T; Brenna, E; Eriksson, G; Holte, S; Källén, AG; Naustdal, T; Persson, CG; Storstein, L; Syvertsen, U; Vilsvik, JS, 1990) |
| "Fifteen asthmatic outpatients were randomly treated during two periods of 14 days each with sustained-release preparations of either enprofylline (3-propyl-xanthine) or theophylline (Theo-Dur) in a double-blind crossover study." | 5.06 | Enprofylline and theophylline slow-eroding tablets in the treatment of asthma: a comparison. ( Eriksson, G; Laursen, LC; Weeke, B, 1986) |
| "Five different doses of enprofylline, a 3-propylxanthine, were compared with a standard dose of theophylline in 135 episodes of acute asthma in a double-blind study." | 5.06 | Efficacy of enprofylline, a new bronchodilating xanthine, in acute asthma. ( Boe, J; Eriksson, G; Ljungholm, K, 1987) |
| "The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients." | 5.06 | Effect of theophylline and enprofylline on bronchial hyperresponsiveness. ( Boorsma, M; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1989) |
| "The bronchodilating effect of two doses of peroral enprofylline was compared with placebo in 24 asthmatic patients." | 5.05 | Enprofylline--effects of a new bronchodilating xanthine derivative in asthmatic patients. ( Dirksen, A; Djurup, R; Johannesson, N; Laursen, LC; Munch, EP; Taudorf, E; Weeke, B, 1983) |
| "In 6 asthmatic patients, the possibility of obtaining a steady state plasma level of 5 mg/l of enprofylline by administration of two constant rate infusions was examined." | 5.05 | Intravenous administration of enprofylline to asthmatic patients. ( Fagerström, PO; Johannesson, N; Laursen, LC; Weeke, B, 1983) |
| "Twenty-five asthmatic outpatients were treated for 3 one-week periods with either enprofylline slowly eroding 300 mg tablets t." | 5.05 | Continuous treatment of asthmatic patients with enprofylline and theophylline. ( Johannesson, N; Laursen, LC; Weeke, B, 1984) |
| "The bronchodilator effect and side-effects of a single oral dose of enprofylline were compared with the corresponding actions of a therapeutic dose of theophylline in 20 asthmatic patients, in a randomized cross-over clinical trial." | 5.05 | Comparison of oral enprofylline and theophylline in asthmatic patients. ( Johannesson, N; Laursen, LC; Søndergaard, I; Weeke, B, 1984) |
| "Eight asthmatic out-patients with a history of exercise-induced asthma (EIA) were randomly treated with intravenously administered enprofylline 1." | 5.05 | Effects of enprofylline and theophylline on exercise-induced asthma. ( Johannesson, N; Laursen, LC; Weeke, B, 1985) |
| " In separate studies we found that enprofylline, an antiasthmatic previously thought to lack adenosine antagonistic properties, is as effective as theophylline as an antagonist of A2b receptors at concentrations achieved clinically." | 3.69 | Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. ( Biaggioni, I; Feoktistov, I, 1995) |
| "Several lines of evidence support the hypothesis that adenosine contributes to asthma." | 3.69 | Role of adenosine in asthma. ( Biaggioni, I; Feoktistov, I, 1996) |
| "Nine patients (3 women), aged 29-78 years, with acute asthma were treated with the antiasthma xanthine, enprofylline, in an open-design study without a reference drug." | 3.67 | Intravenous infusion of enprofylline with an exponentially decreasing drug concentration in acute asthma. ( Arnman, K; Borgström, L; Conradson, TB; Willén, B, 1989) |
| "The pharmacokinetics of enprofylline (3-propylxanthine) were studied in 10 children with asthma (mean age 7." | 3.67 | Pharmacokinetics of enprofylline administered intravenously and as a sustained-release tablet at steady state in children with asthma. ( Simons, FE; Simons, KJ; Watson, WT, 1988) |
| "The pharmacokinetics of intravenous enprofylline has been studied in 8 children with asthma." | 3.67 | Enprofylline pharmacokinetics in children with asthma. ( Borgå, O; Hultqvist, C, 1987) |
| "Enprofylline is a novel xanthine derivative with negligible adenosine antagonizing ability." | 2.66 | Additive bronchodilator effects of terbutaline and enprofylline in asthma. ( Lunell, E; Rasmussen, JB, 1987) |
| "Enprofylline is a potent bronchodilating xanthine derivative that has been shown to have little or no ability to antagonize adenosine in a variety of cell types." | 2.65 | A novel bronchodilator xanthine apparently without adenosine receptor antagonism and tremorogenic effect. ( Andersson, KE; Lunell, E; Persson, CG; Svedmyr, N, 1983) |
| "Enprofylline is a more potent smooth muscle relaxant and antiasthmatic drug than theophylline but does not produce, e." | 2.37 | Effects of enprofylline and theophylline may show the role of adenosine. ( Andersson, KE; Kjellin, G; Persson, CG, 1986) |
| "Enprofylline was given i." | 1.27 | Intravenous enprofylline in asthma patients. ( Andersson, KE; Lunell, E; Persson, CG; Svedmyr, N, 1984) |
| "Pretreatment with lidocaine, the beta-receptor agonist, terbutaline, or the adenosine non-blocking xanthine, enprofylline, inhibited the capsaicine induced inflammatory response." | 1.27 | Anti-asthma drugs and capsaicine-induced microvascular effects in lower airways. ( Erjefält, I; Persson, CG, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (79.49) | 18.7374 |
| 1990's | 8 (20.51) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pauwels, R | 1 |
| Lunell, E | 3 |
| Svedmyr, N | 2 |
| Andersson, KE | 3 |
| Persson, CG | 12 |
| Laursen, LC | 7 |
| Johannesson, N | 5 |
| Dirksen, A | 1 |
| Djurup, R | 1 |
| Munch, EP | 1 |
| Taudorf, E | 1 |
| Weeke, B | 6 |
| Fagerström, PO | 1 |
| Søndergaard, I | 1 |
| Kjellin, G | 2 |
| Erjefält, I | 3 |
| Karlsson, JA | 1 |
| Feoktistov, I | 2 |
| Biaggioni, I | 2 |
| Chapman, KR | 2 |
| Ljungholm, K | 2 |
| Kallen, A | 1 |
| Fozard, JR | 1 |
| Hannon, JP | 1 |
| Janson, C | 1 |
| Gislason, T | 1 |
| Laxmyr, L | 1 |
| Boman, G | 1 |
| Persson, C | 1 |
| Sandström, T | 1 |
| Andersen, JR | 1 |
| Boethius, G | 1 |
| Eriksson, G | 5 |
| Hagman, A | 1 |
| Helsted, M | 1 |
| Lund, B | 1 |
| Matsols, H | 1 |
| Månsson, T | 1 |
| Rosenhall, L | 1 |
| Vilsvik, JS | 1 |
| Amundsen, T | 1 |
| Brenna, E | 1 |
| Naustdal, T | 1 |
| Syvertsen, U | 1 |
| Storstein, L | 1 |
| Källén, AG | 1 |
| Holte, S | 1 |
| Conradson, TB | 2 |
| Eklundh, G | 1 |
| Olofsson, B | 1 |
| Pahlm, O | 1 |
| Persson, G | 1 |
| Clarke, H | 1 |
| Cushley, MJ | 2 |
| Holgate, ST | 2 |
| Bryant, D | 2 |
| Marlin, GE | 1 |
| Mitchell, C | 2 |
| Ruffin, R | 2 |
| Inouye, T | 1 |
| Pedersen, B | 1 |
| Koskinen, S | 1 |
| Osen, SS | 1 |
| Ringdal, N | 1 |
| Koëter, GH | 1 |
| Kraan, J | 1 |
| Boorsma, M | 1 |
| Jonkman, JH | 1 |
| van der Mark, TW | 1 |
| Arnman, K | 1 |
| Willén, B | 1 |
| Borgström, L | 1 |
| Chung, KF | 1 |
| Barnes, PJ | 1 |
| Chapman, BJ | 1 |
| McDonald, C | 1 |
| Capewell, S | 1 |
| Frame, MH | 1 |
| Crompton, GK | 1 |
| Burdon, J | 1 |
| Marlin, G | 1 |
| O'Hehir, R | 1 |
| Wilson, J | 1 |
| Woolcock, A | 1 |
| Webb, S | 1 |
| Mann, JS | 1 |
| Church, MK | 1 |
| Watson, WT | 1 |
| Simons, KJ | 1 |
| Simons, FE | 1 |
| Haahtela, T | 1 |
| Venho, K | 1 |
| Rasmussen, JB | 1 |
| Boe, J | 1 |
| Hultqvist, C | 1 |
| Borgå, O | 1 |
8 reviews available for enprofylline and Asthma
| Article | Year |
|---|---|
[Animal experiments and clinical studies on the role of adenosine in bronchial asthma].
Topics: Adenosine; Adult; Animals; Asthma; Atropine; Basophils; Bronchi; Bronchodilator Agents; Cromolyn Sod | 1984 |
The profile of action of enprofylline, or why adenosine antagonism seems less desirable with xanthine antiasthmatics.
Topics: Adenosine; Animals; Asthma; Bronchi; Cats; Central Nervous System; Chemical Phenomena; Chemistry; Di | 1983 |
Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Humans; Ligands; Lung Diseases, Obstr | 1999 |
Respiratory and allergic disease. I.
Topics: Asthma; Bronchodilator Agents; Delayed-Action Preparations; Histamine H1 Antagonists; Humans; Nedocr | 1988 |
Effects of enprofylline and theophylline may show the role of adenosine.
Topics: Adenosine; Animals; Asthma; Brain; Bronchodilator Agents; Caffeine; Diuresis; Fatty Acids, Nonesteri | 1986 |
Mechanisms and significance of adenosine-induced bronchoconstriction in asthma.
Topics: Adenosine; Adenosine Monophosphate; Airway Obstruction; Aminophylline; Asthma; Bronchi; Bronchodilat | 1987 |
Anti asthmatic effects and pharmacokinetics of enprofylline--a new xanthine derivate.
Topics: Administration, Oral; Asthma; Bronchi; Female; Humans; Infusions, Intravenous; Male; Theophylline; X | 1987 |
Development of safer xanthine drugs for treatment of obstructive airways disease.
Topics: Adenosine; Animals; Asthma; Brain; Cardiovascular System; Humans; Lung; Lung Diseases, Obstructive; | 1986 |
20 trials available for enprofylline and Asthma
| Article | Year |
|---|---|
A novel bronchodilator xanthine apparently without adenosine receptor antagonism and tremorogenic effect.
Topics: Adult; Aged; Asthma; Blood Pressure; Bronchodilator Agents; Clinical Trials as Topic; Double-Blind M | 1983 |
Enprofylline--effects of a new bronchodilating xanthine derivative in asthmatic patients.
Topics: Adult; Asthma; Blood Pressure; Bronchi; Clinical Trials as Topic; Double-Blind Method; Female; Half- | 1983 |
Intravenous administration of enprofylline to asthmatic patients.
Topics: Adult; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Infusions, Parenteral; | 1983 |
Continuous treatment of asthmatic patients with enprofylline and theophylline.
Topics: Adult; Aged; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Double-Blind Method; Female; H | 1984 |
Comparison of oral enprofylline and theophylline in asthmatic patients.
Topics: Administration, Oral; Adult; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Spiro | 1984 |
Long-term xanthine therapy of asthma. Enprofylline and theophylline compared. International Enprofylline Study Group.
Topics: Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Humans; Male; M | 1994 |
Sleep disturbances in asthma: theophylline versus enprofylline.
Topics: Adult; Aged; Aminophylline; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Sleep | 1991 |
Efficacy of enprofylline in acute airway obstruction.
Topics: Acute Disease; Aged; Airway Obstruction; Asthma; Denmark; Female; Humans; Infusions, Intravenous; Ma | 1991 |
Comparison between theophylline and an adenosine non-blocking xanthine in acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Asthma; Bronchodilator Agents; Double- | 1990 |
Arrhythmogenicity from combined bronchodilator therapy in patients with obstructive lung disease and concomitant ischemic heart disease.
Topics: Aged; Asthma; Bronchitis; Cardiac Complexes, Premature; Clinical Trials as Topic; Coronary Disease; | 1987 |
The protective effects of intravenous theophylline and enprofylline against histamine- and adenosine 5'-monophosphate-provoked bronchoconstriction: implications for the mechanisms of action of xanthine derivatives in asthma.
Topics: Adult; Allergens; Asthma; Bronchoconstriction; Bronchodilator Agents; Cyclic AMP; Female; Forced Exp | 1989 |
A placebo-controlled dose-response study of enprofylline in the maintenance therapy of asthma.
Topics: Adult; Aged; Asthma; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration | 1989 |
Effect of theophylline and enprofylline on bronchial hyperresponsiveness.
Topics: Adult; Airway Resistance; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Doubl | 1989 |
Enprofylline in chronic asthma.
Topics: Adult; Aged; Aminophylline; Asthma; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic | 1988 |
Comparison of the effects of nebulized terbutaline with intravenous enprofylline in patients with acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Dou | 1988 |
Comparison of enprofylline and theophylline for intravenous treatment of acute asthma.
Topics: Acute Disease; Adult; Aged; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Female; Humans; | 1986 |
Enprofylline and theophylline slow-eroding tablets in the treatment of asthma: a comparison.
Topics: Adult; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Headache; | 1986 |
Additive bronchodilator effects of terbutaline and enprofylline in asthma.
Topics: Adult; Aged; Asthma; Blood Pressure; Bronchodilator Agents; Drug Synergism; Female; Forced Expirator | 1987 |
Efficacy of enprofylline, a new bronchodilating xanthine, in acute asthma.
Topics: Adult; Aged; Asthma; Blood Pressure; Bronchodilator Agents; Female; Heart Rate; Humans; Male; Middle | 1987 |
Effects of enprofylline and theophylline on exercise-induced asthma.
Topics: Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Clinical Trials as Topic; Double-Blind Method; | 1985 |
11 other studies available for enprofylline and Asthma
| Article | Year |
|---|---|
Intravenous enprofylline in asthma patients.
Topics: Adult; Aged; Asthma; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eva | 1984 |
Enprofylline, a principally new antiasthmatic xanthine.
Topics: Animals; Asthma; Cats; Guinea Pigs; In Vitro Techniques; Male; Mice; Theophylline; Xanthines | 1981 |
Adenosine antagonism, a less desirable characteristic of xanthine asthma drugs?
Topics: Adenosine; Animals; Asthma; Guinea Pigs; Humans; In Vitro Techniques; Male; Mice; Motor Activity; Mu | 1981 |
Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Anti-Asthmatic Agents; Asthma; Calcium; Cyclic AMP; Hu | 1995 |
Role of adenosine in asthma.
Topics: Adenosine; Adrenergic beta-Antagonists; Animals; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; | 1996 |
Pharmacologic control of plasma exudation into tracheobronchial airways.
Topics: Animals; Asthma; Bronchi; Bronchodilator Agents; Capillary Permeability; Cromolyn Sodium; Guinea Pig | 1991 |
Intravenous infusion of enprofylline with an exponentially decreasing drug concentration in acute asthma.
Topics: Adult; Aged; Asthma; Blood Pressure; Body Weight; Bronchodilator Agents; Female; Heart Rate; Humans; | 1989 |
Pharmacokinetics of enprofylline administered intravenously and as a sustained-release tablet at steady state in children with asthma.
Topics: Asthma; Child; Delayed-Action Preparations; Female; Half-Life; Humans; Injections, Intravenous; Male | 1988 |
Enprofylline pharmacokinetics in children with asthma.
Topics: Asthma; Child; Female; Half-Life; Humans; Kinetics; Male; Metabolic Clearance Rate; Xanthines | 1987 |
[Enprofylline--a new therapeutic possibility in asthma and other obstructive lung diseases].
Topics: Asthma; Bronchodilator Agents; Humans; Lung Diseases, Obstructive; Xanthines | 1985 |
Anti-asthma drugs and capsaicine-induced microvascular effects in lower airways.
Topics: Animals; Asthma; Bronchodilator Agents; Capillary Permeability; Capsaicin; Guinea Pigs; Lidocaine; M | 1985 |